Dainippon Sumitomo Pharma

Dainippon Sumitomo Pharma to acquire Boston Biomedical

Thursday, March 1, 2012 10:54 AM

Dainippon Sumitomo Pharma (DSP) of Osaka, Japan, plans to acquire Norwood, Mass.-based Boston Biomedical (BBI).

More... »


Dainippon Sumitomo Pharma and Intercept Pharmaceuticals partner

Friday, April 1, 2011 11:47 AM

Japan-based Dainippon Sumitomo Pharma (DSP) and U.S.-based Intercept Pharmaceuticals announced an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid (OCA, also known as INT-747), according to FierceBiotech. DSP will advance OCA in Japan and China for the treatment of chronic liver diseases, initially focusing on primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH).

More... »



CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs